Omacetaxine mepesuccinate (synribo) – newly launched in chronic myeloid leukemia

Author： Nazha Aziz   Kantarjian Hagop   Cortes Jorge   Quintás-Cardama Alfonso  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.14, Iss.14, 2013-10, pp. : 1977-1986

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Omacetaxine mepesuccinate for the treatment of leukemia

By Kim Theo Daniel   Frick Mareike   le Coutre Philipp  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 15, 2011-10 ,pp. : 2381-2392

Informa Healthcare

Access to resources Recommend Favorite

The current role of high-dose imatinib in chronic myeloid leukemia patients, newly diagnosed or resistant to standard dose

By Breccia Massimo   Alimena Giuliana  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 13, 2011-09 ,pp. : 2075-2087

Informa Healthcare

Access to resources Recommend Favorite

Second-Generation Tyrosine Kinase Inhibitors as First-Line Treatment Strategy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients

By  

Current Cancer Drug Targets, Vol. 12, Iss. 4, 2012-04 ,pp. : 391-401

Bentham Science Publishers

Access to resources Recommend Favorite

Treatment options for chronic myeloid leukemia

By Tanaka Maria Florencia   Kantarjian Hagop   Cortes Jorge   Ohanian Maro   Jabbour Elias  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 6, 2012-04 ,pp. : 815-828

Informa Healthcare

Access to resources Recommend Favorite

Emerging drugs for chronic myeloid leukemia

By Cilloni Daniela   Messa Emanuela   Rotolo Antonia   Saglio Giuseppe  

Expert Opinion on Emerging Drugs, Vol. 15, Iss. 2, 2010-06 ,pp. : 175-184

Informa Healthcare

Access to resources Recommend Favorite